CEMPRA, INC. (MLNT) [Rocket]

Overview

CEMPRA, INC. (MLNT)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
06/24/2020	SC TO-T/A	Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
06/24/2020	GN	Melinta Therapeutics Announces Termination of Merger Agreement and Tender Offer for Shares of Tetraphase
06/12/2020	SC TO-T	Form SC TO-T - Tender offer statement by Third Party:
06/09/2020	GN	Melinta Therapeutics Enters Into Agreement to Acquire Tetraphase Pharmaceuticals
04/20/2020	S-3DPOS	Form S-3DPOS - Post-effective amendments, registration of securities, dividend or interest reinvestment plans, immediately effective:
04/20/2020	S-3DPOS	Form S-3DPOS - Post-effective amendments, registration of securities, dividend or interest reinvestment plans, immediately effective:
04/20/2020	S-3DPOS	Form S-3DPOS - Post-effective amendments, registration of securities, dividend or interest reinvestment plans, immediately effective:

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14	Dec-31-13	Dec-31-12	Dec-31-11
Revenues	137.5	33.9	0.0	0.0	15.2	7.8	0.0	0.0
Revenue growth	306.0%			-100.0%	94.8%
Cost of goods sold	41.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross profit	96.4	33.9	0.0	0.0	15.2	7.8	0.0	0.0
Gross margin	70.1%	100.0%			100.0%	100.0%
Selling, general and administrative	133.3	63.3	19.4	14.2
Research and development	55.4	49.5	49.8	62.8	62.5	41.3	16.9	16.9
General and administrative					12.1	9.4	6.1	3.7
EBITA	-127.3	-78.9	-69.2	-76.9	-59.4	-42.9	-22.9	-20.6
EBITA margin	-92.6%	-233.1%			-390.4%	-549.3%
Amortization of intangibles	16.3
EBIT	-143.6	-78.9	-69.2	-76.9	-59.4	-42.9	-22.9	-20.6
EBIT margin	-104.5%	-233.1%			-390.4%	-549.3%
Pre-tax income	-157.3	-59.0	-73.9	-78.7	-61.6	-45.0	-24.2	-21.2
Income taxes	-0.1	-0.1	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.1%	0.2%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-157.2	-78.2	-95.0	-94.9	-61.6	-45.0	-24.5	-25.0
Net margin	-114.3%	-230.8%			-405.2%	-576.4%

Diluted EPS	($17.12)	($109.28)	($20,600.13)	($26,171.49)	($1.81)	($1.53)	($1.23)	($47.53)
Shares outstanding (diluted)	9.2	0.7	0.0	0.0	34.1	29.4	19.9	0.5

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.